NCT06104839 Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
| NCT ID | NCT06104839 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | NEXTGEN Bioscience |
| Condition | Alopecia Areata |
| Study Type | INTERVENTIONAL |
| Enrollment | 73 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 73 participants in total. It began in 2024-09-01 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).
Eligibility Criteria
Inclusion Criteria: * Men or women between ≥19 and ≤65 years of age at the time of informed consent * Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT \< 95% at Screening and Day 1/Baseline * Current episode of hair loss for ≥6 months but \<8 years * Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator * Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study Exclusion Criteria: * Participants with the following medical history confirmed during screening: * ohter Types of alopecia other than alopecia areata (such as cicatricial/scarring alopecia \[including central centrifugal cicatricial alopecia\], traction alopecia, androgenic alopecia, telogen effluvium, etc.) * Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment * Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06104839 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 65 Years, studying Alopecia Areata. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06104839 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06104839 currently recruiting?
Yes, NCT06104839 is actively recruiting participants. Contact the research team at flower@nextgenbio.co.kr for enrollment information.
Where is the NCT06104839 trial being conducted?
This trial is being conducted at Seoul, South Korea, Seoul, South Korea.
Who is sponsoring the NCT06104839 clinical trial?
NCT06104839 is sponsored by NEXTGEN Bioscience. The trial plans to enroll 73 participants.